Global Trastuzumab Injection Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Trastuzumab Injection Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Trastuzumab is a targeted cancer drug and is also known by other names such as Herceptin, Herzuma and Ontruzant. It is a treatment for early and advanced breast cancer, advanced stomach cancer and cancer of where the food pipe joins your stomach (gastro oesophageal junction). Trastuzumab injection products are used with other medications or after other medications have been used to treat a certain type of breast cancer that has spread to other parts of the body. Trastuzumab injection products are also used during and after treatment with other medications to decrease the chance that a certain type of breast cancer will return. Trastuzumab injection products are also used with other medications to treat certain types of stomach cancer that have spread to other parts of the body. Trastuzumab is in a class of medications called monoclonal antibodies. It works by stopping the growth of cancer cells.
Trastuzumab Injection report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Trastuzumab Injection market is projected to reach US$ 1098.8 million in 2029, increasing from US$ 775 million in 2022, with the CAGR of 5.3% during the period of 2024 to 2029. Demand from Hospitals and Clinics are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Trastuzumab Injection industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029.
Globally, Trastuzumab Injection key manufacturers include Pfizer, Roche, Celltrion, Amgen, Samsung Bioepsis, Mylan, Glenmark, AstraZeneca and Remegen Co., Ltd., etc. Pfizer, Roche, Celltrion are top 3 players and held % sales share in total in 2022.
Trastuzumab Injection can be divided into 60 mg, 150 mg, 440 mg and Others, etc. 60 mg is the mainstream product in the market, accounting for % sales share globally in 2022.
Trastuzumab Injection is widely used in various fields, such as Hospitals, Clinics and Others,, etc. Hospitals provides greatest supports to the Trastuzumab Injection industry development. In 2022, global % sales of Trastuzumab Injection went into Hospitals filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Trastuzumab Injection market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Pfizer
Roche
Celltrion
Amgen
Samsung Bioepsis
Mylan
Glenmark
AstraZeneca
Remegen Co., Ltd.
Hisun Biopharmaceutical
Shanghai Henlius Biotech
Segment by Type
60 mg
150 mg
440 mg
Others
Hospitals
Clinics
Others
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Trastuzumab Injection market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Trastuzumab Injection, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Trastuzumab Injection industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Trastuzumab Injection in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Trastuzumab Injection introduction, etc. Trastuzumab Injection Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Trastuzumab Injection market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Trastuzumab Injection report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Trastuzumab Injection market is projected to reach US$ 1098.8 million in 2029, increasing from US$ 775 million in 2022, with the CAGR of 5.3% during the period of 2024 to 2029. Demand from Hospitals and Clinics are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Trastuzumab Injection industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029.
Globally, Trastuzumab Injection key manufacturers include Pfizer, Roche, Celltrion, Amgen, Samsung Bioepsis, Mylan, Glenmark, AstraZeneca and Remegen Co., Ltd., etc. Pfizer, Roche, Celltrion are top 3 players and held % sales share in total in 2022.
Trastuzumab Injection can be divided into 60 mg, 150 mg, 440 mg and Others, etc. 60 mg is the mainstream product in the market, accounting for % sales share globally in 2022.
Trastuzumab Injection is widely used in various fields, such as Hospitals, Clinics and Others,, etc. Hospitals provides greatest supports to the Trastuzumab Injection industry development. In 2022, global % sales of Trastuzumab Injection went into Hospitals filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Trastuzumab Injection market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Pfizer
Roche
Celltrion
Amgen
Samsung Bioepsis
Mylan
Glenmark
AstraZeneca
Remegen Co., Ltd.
Hisun Biopharmaceutical
Shanghai Henlius Biotech
Segment by Type
60 mg
150 mg
440 mg
Others
Segment by Application
Hospitals
Clinics
Others
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Trastuzumab Injection market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Trastuzumab Injection, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Trastuzumab Injection industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Trastuzumab Injection in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Trastuzumab Injection introduction, etc. Trastuzumab Injection Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Trastuzumab Injection market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices